devd-afc (caspase-3 Search Results


90
MBL Life science caspase-3 assay ac-devd-afc substrate
Caspase 3 Assay Ac Devd Afc Substrate, supplied by MBL Life science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/caspase+3+assay+ac+devd+afc+substrate/pmc00556396-285-12-14
Average 90 stars, based on 1 article reviews
caspase-3 assay ac-devd-afc substrate - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Bachem caspase substrate ac-devd-afc
Caspase Substrate Ac Devd Afc, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/caspase+3+substrate+ac+devd+afc/pmc03328137-53-0-6
Average 90 stars, based on 1 article reviews
caspase substrate ac-devd-afc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pharmagen gmbh ac-devd-afc caspase-3 fluorigenic substrate kits
Ac Devd Afc Caspase 3 Fluorigenic Substrate Kits, supplied by Pharmagen gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/ac+devd+afc+caspase+3+fluorigenic+substrate+kits/pm22484917-95-52-55
Average 90 stars, based on 1 article reviews
ac-devd-afc caspase-3 fluorigenic substrate kits - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Becton Dickinson caspase 3 activity reporter ac-devd-afc
Trastuzumab causes cell cycle arrest and cell death in trastuzumab-hypersensitive cells. Trastuzumab-resistant and trastuzumab-hypersensitive models maintain HER2 levels ( A - E ). HER2 surface levels were analyzed by flow cytometry ( A ), immunofluorescence ( B ) and cell surface immunoprecipitation ( E ) using trastuzumab 10 nM as primary antibody in all cases. Total HER2 levels were determined by immunofluorescence ( C ) or western blot ( D ). Levels of total ( D ) and cell surface tyrosine-phosphorylated HER2 were determined by western blot. For immunofluorescence, cells were fixed and stained for HER2 using trastuzumab (green) ( B ) or an anti-HER2 antibody (red) ( C ) and DNA (blue). Scale bar, 10 μm. F Evaluation of S phase entry upon trastuzumab treatment. Cells were treated with trastuzumab for 5 days, received a 10 μM pulse of BrdU and BrdU incorporation was determined by flow cytometry. Data is represented as the mean ± SD, normalized to untreated controls of two independent experiments. G Effect of trastuzumab on cell death. Cells were treated with trastuzumab for 6 days and stained with annexin V-FITC and propidium iodide, followed by flow cytometry analysis. The graph shows mean ± SD of viable and non-viable cells from two independent experiments. I Trastuzumab treatment induces <t>caspase</t> <t>3</t> activation in BTSH cells. Cells were treated with trastuzumab for 6 days and <t>caspase</t> <t>3</t> activity was determined by fluorometric techniques using a caspase 3 specific substrate. H Analysis of proapoptotic and cell cycle progression proteins after trastuzumab treatment. Cells were treated with trastuzumab for 6 days and the amount of the indicated proteins was assessed by western blot. cCaspase stands for cleavage caspase. Calnexin was used as a loading control. C: control; T: trastuzumab; IP: immunoprecipitation; WB: western blot
Caspase 3 Activity Reporter Ac Devd Afc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/caspase+3+activity+reporter+ac+devd+afc/pmc08496101-63-15-20
Average 90 stars, based on 1 article reviews
caspase 3 activity reporter ac-devd-afc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Becton Dickinson caspase-3-like substrate ac-devdafc
Trastuzumab causes cell cycle arrest and cell death in trastuzumab-hypersensitive cells. Trastuzumab-resistant and trastuzumab-hypersensitive models maintain HER2 levels ( A - E ). HER2 surface levels were analyzed by flow cytometry ( A ), immunofluorescence ( B ) and cell surface immunoprecipitation ( E ) using trastuzumab 10 nM as primary antibody in all cases. Total HER2 levels were determined by immunofluorescence ( C ) or western blot ( D ). Levels of total ( D ) and cell surface tyrosine-phosphorylated HER2 were determined by western blot. For immunofluorescence, cells were fixed and stained for HER2 using trastuzumab (green) ( B ) or an anti-HER2 antibody (red) ( C ) and DNA (blue). Scale bar, 10 μm. F Evaluation of S phase entry upon trastuzumab treatment. Cells were treated with trastuzumab for 5 days, received a 10 μM pulse of BrdU and BrdU incorporation was determined by flow cytometry. Data is represented as the mean ± SD, normalized to untreated controls of two independent experiments. G Effect of trastuzumab on cell death. Cells were treated with trastuzumab for 6 days and stained with annexin V-FITC and propidium iodide, followed by flow cytometry analysis. The graph shows mean ± SD of viable and non-viable cells from two independent experiments. I Trastuzumab treatment induces <t>caspase</t> <t>3</t> activation in BTSH cells. Cells were treated with trastuzumab for 6 days and <t>caspase</t> <t>3</t> activity was determined by fluorometric techniques using a caspase 3 specific substrate. H Analysis of proapoptotic and cell cycle progression proteins after trastuzumab treatment. Cells were treated with trastuzumab for 6 days and the amount of the indicated proteins was assessed by western blot. cCaspase stands for cleavage caspase. Calnexin was used as a loading control. C: control; T: trastuzumab; IP: immunoprecipitation; WB: western blot
Caspase 3 Like Substrate Ac Devdafc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/caspase+3+like+substrate+ac+devdafc/pm26031348-82-0-6
Average 90 stars, based on 1 article reviews
caspase-3-like substrate ac-devdafc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Geno Tech Inc caspase-3 ac-devdafc
Trastuzumab causes cell cycle arrest and cell death in trastuzumab-hypersensitive cells. Trastuzumab-resistant and trastuzumab-hypersensitive models maintain HER2 levels ( A - E ). HER2 surface levels were analyzed by flow cytometry ( A ), immunofluorescence ( B ) and cell surface immunoprecipitation ( E ) using trastuzumab 10 nM as primary antibody in all cases. Total HER2 levels were determined by immunofluorescence ( C ) or western blot ( D ). Levels of total ( D ) and cell surface tyrosine-phosphorylated HER2 were determined by western blot. For immunofluorescence, cells were fixed and stained for HER2 using trastuzumab (green) ( B ) or an anti-HER2 antibody (red) ( C ) and DNA (blue). Scale bar, 10 μm. F Evaluation of S phase entry upon trastuzumab treatment. Cells were treated with trastuzumab for 5 days, received a 10 μM pulse of BrdU and BrdU incorporation was determined by flow cytometry. Data is represented as the mean ± SD, normalized to untreated controls of two independent experiments. G Effect of trastuzumab on cell death. Cells were treated with trastuzumab for 6 days and stained with annexin V-FITC and propidium iodide, followed by flow cytometry analysis. The graph shows mean ± SD of viable and non-viable cells from two independent experiments. I Trastuzumab treatment induces <t>caspase</t> <t>3</t> activation in BTSH cells. Cells were treated with trastuzumab for 6 days and <t>caspase</t> <t>3</t> activity was determined by fluorometric techniques using a caspase 3 specific substrate. H Analysis of proapoptotic and cell cycle progression proteins after trastuzumab treatment. Cells were treated with trastuzumab for 6 days and the amount of the indicated proteins was assessed by western blot. cCaspase stands for cleavage caspase. Calnexin was used as a loading control. C: control; T: trastuzumab; IP: immunoprecipitation; WB: western blot
Caspase 3 Ac Devdafc, supplied by Geno Tech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/caspase+3+ac+devdafc/pm11374438-39-0-10
Average 90 stars, based on 1 article reviews
caspase-3 ac-devdafc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Boehringer Mannheim fluorescence-generating caspase-3 specific substrate devd-afc
Trastuzumab causes cell cycle arrest and cell death in trastuzumab-hypersensitive cells. Trastuzumab-resistant and trastuzumab-hypersensitive models maintain HER2 levels ( A - E ). HER2 surface levels were analyzed by flow cytometry ( A ), immunofluorescence ( B ) and cell surface immunoprecipitation ( E ) using trastuzumab 10 nM as primary antibody in all cases. Total HER2 levels were determined by immunofluorescence ( C ) or western blot ( D ). Levels of total ( D ) and cell surface tyrosine-phosphorylated HER2 were determined by western blot. For immunofluorescence, cells were fixed and stained for HER2 using trastuzumab (green) ( B ) or an anti-HER2 antibody (red) ( C ) and DNA (blue). Scale bar, 10 μm. F Evaluation of S phase entry upon trastuzumab treatment. Cells were treated with trastuzumab for 5 days, received a 10 μM pulse of BrdU and BrdU incorporation was determined by flow cytometry. Data is represented as the mean ± SD, normalized to untreated controls of two independent experiments. G Effect of trastuzumab on cell death. Cells were treated with trastuzumab for 6 days and stained with annexin V-FITC and propidium iodide, followed by flow cytometry analysis. The graph shows mean ± SD of viable and non-viable cells from two independent experiments. I Trastuzumab treatment induces <t>caspase</t> <t>3</t> activation in BTSH cells. Cells were treated with trastuzumab for 6 days and <t>caspase</t> <t>3</t> activity was determined by fluorometric techniques using a caspase 3 specific substrate. H Analysis of proapoptotic and cell cycle progression proteins after trastuzumab treatment. Cells were treated with trastuzumab for 6 days and the amount of the indicated proteins was assessed by western blot. cCaspase stands for cleavage caspase. Calnexin was used as a loading control. C: control; T: trastuzumab; IP: immunoprecipitation; WB: western blot
Fluorescence Generating Caspase 3 Specific Substrate Devd Afc, supplied by Boehringer Mannheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/fluorescence+generating+caspase+3+specific+substrate+devd+afc/pm15686661-36-15-16
Average 90 stars, based on 1 article reviews
fluorescence-generating caspase-3 specific substrate devd-afc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BioAssay Systems LLC fluorogenic caspase 3 substrate n-ac-devd-afc
Trastuzumab causes cell cycle arrest and cell death in trastuzumab-hypersensitive cells. Trastuzumab-resistant and trastuzumab-hypersensitive models maintain HER2 levels ( A - E ). HER2 surface levels were analyzed by flow cytometry ( A ), immunofluorescence ( B ) and cell surface immunoprecipitation ( E ) using trastuzumab 10 nM as primary antibody in all cases. Total HER2 levels were determined by immunofluorescence ( C ) or western blot ( D ). Levels of total ( D ) and cell surface tyrosine-phosphorylated HER2 were determined by western blot. For immunofluorescence, cells were fixed and stained for HER2 using trastuzumab (green) ( B ) or an anti-HER2 antibody (red) ( C ) and DNA (blue). Scale bar, 10 μm. F Evaluation of S phase entry upon trastuzumab treatment. Cells were treated with trastuzumab for 5 days, received a 10 μM pulse of BrdU and BrdU incorporation was determined by flow cytometry. Data is represented as the mean ± SD, normalized to untreated controls of two independent experiments. G Effect of trastuzumab on cell death. Cells were treated with trastuzumab for 6 days and stained with annexin V-FITC and propidium iodide, followed by flow cytometry analysis. The graph shows mean ± SD of viable and non-viable cells from two independent experiments. I Trastuzumab treatment induces <t>caspase</t> <t>3</t> activation in BTSH cells. Cells were treated with trastuzumab for 6 days and <t>caspase</t> <t>3</t> activity was determined by fluorometric techniques using a caspase 3 specific substrate. H Analysis of proapoptotic and cell cycle progression proteins after trastuzumab treatment. Cells were treated with trastuzumab for 6 days and the amount of the indicated proteins was assessed by western blot. cCaspase stands for cleavage caspase. Calnexin was used as a loading control. C: control; T: trastuzumab; IP: immunoprecipitation; WB: western blot
Fluorogenic Caspase 3 Substrate N Ac Devd Afc, supplied by BioAssay Systems LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/fluorogenic+caspase+3+substrate+n+ac+devd+afc/pm34106437-68-0-9
Average 90 stars, based on 1 article reviews
fluorogenic caspase 3 substrate n-ac-devd-afc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Bachem z-devd-afc (caspase-3 or ccp32 substrate, afc 138)
Trastuzumab causes cell cycle arrest and cell death in trastuzumab-hypersensitive cells. Trastuzumab-resistant and trastuzumab-hypersensitive models maintain HER2 levels ( A - E ). HER2 surface levels were analyzed by flow cytometry ( A ), immunofluorescence ( B ) and cell surface immunoprecipitation ( E ) using trastuzumab 10 nM as primary antibody in all cases. Total HER2 levels were determined by immunofluorescence ( C ) or western blot ( D ). Levels of total ( D ) and cell surface tyrosine-phosphorylated HER2 were determined by western blot. For immunofluorescence, cells were fixed and stained for HER2 using trastuzumab (green) ( B ) or an anti-HER2 antibody (red) ( C ) and DNA (blue). Scale bar, 10 μm. F Evaluation of S phase entry upon trastuzumab treatment. Cells were treated with trastuzumab for 5 days, received a 10 μM pulse of BrdU and BrdU incorporation was determined by flow cytometry. Data is represented as the mean ± SD, normalized to untreated controls of two independent experiments. G Effect of trastuzumab on cell death. Cells were treated with trastuzumab for 6 days and stained with annexin V-FITC and propidium iodide, followed by flow cytometry analysis. The graph shows mean ± SD of viable and non-viable cells from two independent experiments. I Trastuzumab treatment induces <t>caspase</t> <t>3</t> activation in BTSH cells. Cells were treated with trastuzumab for 6 days and <t>caspase</t> <t>3</t> activity was determined by fluorometric techniques using a caspase 3 specific substrate. H Analysis of proapoptotic and cell cycle progression proteins after trastuzumab treatment. Cells were treated with trastuzumab for 6 days and the amount of the indicated proteins was assessed by western blot. cCaspase stands for cleavage caspase. Calnexin was used as a loading control. C: control; T: trastuzumab; IP: immunoprecipitation; WB: western blot
Z Devd Afc (Caspase 3 Or Ccp32 Substrate, Afc 138), supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/z+devd+afc++caspase+3+or+ccp32+substrate++afc+138+/pm11302522-90-18-28
Average 90 stars, based on 1 article reviews
z-devd-afc (caspase-3 or ccp32 substrate, afc 138) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genotech Corp caspase-3, 7, 10 assay kit, with ac-devd-afc substrate
Trastuzumab causes cell cycle arrest and cell death in trastuzumab-hypersensitive cells. Trastuzumab-resistant and trastuzumab-hypersensitive models maintain HER2 levels ( A - E ). HER2 surface levels were analyzed by flow cytometry ( A ), immunofluorescence ( B ) and cell surface immunoprecipitation ( E ) using trastuzumab 10 nM as primary antibody in all cases. Total HER2 levels were determined by immunofluorescence ( C ) or western blot ( D ). Levels of total ( D ) and cell surface tyrosine-phosphorylated HER2 were determined by western blot. For immunofluorescence, cells were fixed and stained for HER2 using trastuzumab (green) ( B ) or an anti-HER2 antibody (red) ( C ) and DNA (blue). Scale bar, 10 μm. F Evaluation of S phase entry upon trastuzumab treatment. Cells were treated with trastuzumab for 5 days, received a 10 μM pulse of BrdU and BrdU incorporation was determined by flow cytometry. Data is represented as the mean ± SD, normalized to untreated controls of two independent experiments. G Effect of trastuzumab on cell death. Cells were treated with trastuzumab for 6 days and stained with annexin V-FITC and propidium iodide, followed by flow cytometry analysis. The graph shows mean ± SD of viable and non-viable cells from two independent experiments. I Trastuzumab treatment induces <t>caspase</t> <t>3</t> activation in BTSH cells. Cells were treated with trastuzumab for 6 days and <t>caspase</t> <t>3</t> activity was determined by fluorometric techniques using a caspase 3 specific substrate. H Analysis of proapoptotic and cell cycle progression proteins after trastuzumab treatment. Cells were treated with trastuzumab for 6 days and the amount of the indicated proteins was assessed by western blot. cCaspase stands for cleavage caspase. Calnexin was used as a loading control. C: control; T: trastuzumab; IP: immunoprecipitation; WB: western blot
Caspase 3, 7, 10 Assay Kit, With Ac Devd Afc Substrate, supplied by Genotech Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/devd-afc+(caspase-3/caspase+3++7++10+assay+kit++with+ac+devd+afc+substrate/pm17052884-94-18-27
Average 90 stars, based on 1 article reviews
caspase-3, 7, 10 assay kit, with ac-devd-afc substrate - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier


Image Search Results


Trastuzumab causes cell cycle arrest and cell death in trastuzumab-hypersensitive cells. Trastuzumab-resistant and trastuzumab-hypersensitive models maintain HER2 levels ( A - E ). HER2 surface levels were analyzed by flow cytometry ( A ), immunofluorescence ( B ) and cell surface immunoprecipitation ( E ) using trastuzumab 10 nM as primary antibody in all cases. Total HER2 levels were determined by immunofluorescence ( C ) or western blot ( D ). Levels of total ( D ) and cell surface tyrosine-phosphorylated HER2 were determined by western blot. For immunofluorescence, cells were fixed and stained for HER2 using trastuzumab (green) ( B ) or an anti-HER2 antibody (red) ( C ) and DNA (blue). Scale bar, 10 μm. F Evaluation of S phase entry upon trastuzumab treatment. Cells were treated with trastuzumab for 5 days, received a 10 μM pulse of BrdU and BrdU incorporation was determined by flow cytometry. Data is represented as the mean ± SD, normalized to untreated controls of two independent experiments. G Effect of trastuzumab on cell death. Cells were treated with trastuzumab for 6 days and stained with annexin V-FITC and propidium iodide, followed by flow cytometry analysis. The graph shows mean ± SD of viable and non-viable cells from two independent experiments. I Trastuzumab treatment induces caspase 3 activation in BTSH cells. Cells were treated with trastuzumab for 6 days and caspase 3 activity was determined by fluorometric techniques using a caspase 3 specific substrate. H Analysis of proapoptotic and cell cycle progression proteins after trastuzumab treatment. Cells were treated with trastuzumab for 6 days and the amount of the indicated proteins was assessed by western blot. cCaspase stands for cleavage caspase. Calnexin was used as a loading control. C: control; T: trastuzumab; IP: immunoprecipitation; WB: western blot

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

doi: 10.1186/s13046-021-02098-z

Figure Lengend Snippet: Trastuzumab causes cell cycle arrest and cell death in trastuzumab-hypersensitive cells. Trastuzumab-resistant and trastuzumab-hypersensitive models maintain HER2 levels ( A - E ). HER2 surface levels were analyzed by flow cytometry ( A ), immunofluorescence ( B ) and cell surface immunoprecipitation ( E ) using trastuzumab 10 nM as primary antibody in all cases. Total HER2 levels were determined by immunofluorescence ( C ) or western blot ( D ). Levels of total ( D ) and cell surface tyrosine-phosphorylated HER2 were determined by western blot. For immunofluorescence, cells were fixed and stained for HER2 using trastuzumab (green) ( B ) or an anti-HER2 antibody (red) ( C ) and DNA (blue). Scale bar, 10 μm. F Evaluation of S phase entry upon trastuzumab treatment. Cells were treated with trastuzumab for 5 days, received a 10 μM pulse of BrdU and BrdU incorporation was determined by flow cytometry. Data is represented as the mean ± SD, normalized to untreated controls of two independent experiments. G Effect of trastuzumab on cell death. Cells were treated with trastuzumab for 6 days and stained with annexin V-FITC and propidium iodide, followed by flow cytometry analysis. The graph shows mean ± SD of viable and non-viable cells from two independent experiments. I Trastuzumab treatment induces caspase 3 activation in BTSH cells. Cells were treated with trastuzumab for 6 days and caspase 3 activity was determined by fluorometric techniques using a caspase 3 specific substrate. H Analysis of proapoptotic and cell cycle progression proteins after trastuzumab treatment. Cells were treated with trastuzumab for 6 days and the amount of the indicated proteins was assessed by western blot. cCaspase stands for cleavage caspase. Calnexin was used as a loading control. C: control; T: trastuzumab; IP: immunoprecipitation; WB: western blot

Article Snippet: Caspase 3 activity after 6 days trastuzumab 50 nM treatment was fluorometrically determined by the caspase 3 activity reporter Ac-DEVD-AFC (BD Biosciences, Palo Alto, USA) as described [ ].

Techniques: Flow Cytometry, Immunofluorescence, Immunoprecipitation, Western Blot, Staining, BrdU Incorporation Assay, Activation Assay, Activity Assay